Donor Myocardial Infarction Impairs the Therapeutic Potential of Bone Marrow Cells by an Interleukin-1-Mediated Inflammatory Response
about
Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysisTargeting interleukin-1 in heart diseaseDifference in mobilization of progenitor cells after myocardial infarction in smoking versus non-smoking patients: insights from the BONAMI trial.Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.The effect of bone marrow microenvironment on the functional properties of the therapeutic bone marrow-derived cells in patients with acute myocardial infarctionAdvanced Donor Age Impairs Bone Marrow Cell Therapeutic Efficacy for Cardiac DiseaseEffect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.Pleiotrophin gene therapy for peripheral ischemia: evaluation of full-length and truncated gene variantsThe time window for therapy with peptide nanofibers combined with autologous bone marrow cells in pigs after acute myocardial infarction.Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.Migration towards SDF-1 selects angiogenin-expressing bone marrow monocytes endowed with cardiac reparative activity in patients with previous myocardial infarction.Benefits of hypoxic culture on bone marrow multipotent stromal cells.Injection of Human Cord Blood Cells With Hyaluronan Improves Postinfarction Cardiac Repair in Pigs.Overexpression of Nitric Oxide Synthase Restores Circulating Angiogenic Cell Function in Patients With Coronary Artery Disease: Implications for Autologous Cell Therapy for Myocardial InfarctionImpact of heart failure on the behavior of human neonatal stem cells in vitro.Current status of cell-based therapy for heart failure.Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke.MicroRNAs, signaling pathways and diseases.A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction.Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis.Mesenchymal stem cell therapy: A promising cell-based therapy for treatment of myocardial infarction.The utility of basic animal research.Donor variability among anti-inflammatory pre-activated mesenchymal stromal cells.
P2860
Q27001633-5E5CB634-6FEF-4C9C-A5E7-12506D0E35FFQ27009347-08F1FEA7-629E-44AF-AEA0-FDAEBA747BDEQ33745962-52B503B4-3A22-44EF-A341-0625B54C3E2EQ34074673-0F760DDF-19CF-4696-8CF0-292902A625F3Q34214191-34EE2455-9201-4A70-AFE4-A145EBBA0D3BQ34295979-CEE2519B-FB6A-48D0-90C4-42DFFB6973FDQ34467911-0003A474-3781-4189-B4F9-1D6FE24FD0F9Q34695480-35A0C2B4-A44A-4806-BDE6-EEEF487F0426Q35165467-01FFF5EA-B902-4FB9-9544-F9236A0A04BCQ35174462-BD60DE57-FA2D-4D5D-8D9D-9C853B9B960EQ35633590-335A7DB4-ACC4-4CCB-8F28-0F01BADD99DAQ36357726-B46C08CF-67BF-46E2-BF56-A15FB34181DCQ36440749-5DDADECA-0452-4623-8E61-A7C2D8299BA5Q36877532-53112E22-BEAA-4175-A71D-D2D0FC5FC83DQ37363436-FEE03B22-C140-44C2-931A-8EE40FFA9AF1Q38090542-EC3C8CD2-1992-415D-A26F-82FBAB1F66BCQ38376997-AA499AE4-466F-44A0-86EE-740281D49400Q39414868-51FD39E4-9E3F-4F02-9703-F03383A2D95EQ41969164-16B06C06-B08F-4853-BCDF-FC15B5CF3A54Q43071165-F17E2A06-95BD-45CF-8E1A-6AABE1406958Q45789970-B059D2FB-8145-4C5C-BEA4-560453301DC4Q46374324-FB26762F-910C-4AD4-A2CB-50FB609776B1Q48320889-B542BB6F-0C51-410A-AAC4-E54AE64A2EC7Q55065461-F456720B-664B-4626-86B3-A590D2FA1DE0
P2860
Donor Myocardial Infarction Impairs the Therapeutic Potential of Bone Marrow Cells by an Interleukin-1-Mediated Inflammatory Response
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Donor Myocardial Infarction Im ...... Mediated Inflammatory Response
@ast
Donor Myocardial Infarction Im ...... Mediated Inflammatory Response
@en
type
label
Donor Myocardial Infarction Im ...... Mediated Inflammatory Response
@ast
Donor Myocardial Infarction Im ...... Mediated Inflammatory Response
@en
prefLabel
Donor Myocardial Infarction Im ...... Mediated Inflammatory Response
@ast
Donor Myocardial Infarction Im ...... Mediated Inflammatory Response
@en
P2093
P2860
P1476
Donor Myocardial Infarction Im ...... Mediated Inflammatory Response
@en
P2093
B. T. Clifford
D. J. Haddad
D. L. Tobler
J. Takagawa
K. Pinnamaneni
L. Carbone
M. J. Bartel
M. L. Hermiston
M. L. Springer
P2860
P304
100ra90-100ra90
P356
10.1126/SCITRANSLMED.3002814
P407
P577
2011-09-14T00:00:00Z